| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
The molecular targets of 2,2-Bis(3-phenyl-4-hydroxyphenyl)propane are not characterized in the available literature. The compound is a bioactive chemical used for the synthesis of active compounds. Its biological activity may be related to its phenolic structure, which could confer antioxidant or other properties. However, specific molecular targets have not been identified. The compound is primarily used as a chemical intermediate.
|
|---|---|
| ln Vitro |
In vitro studies of 2,2-Bis(3-phenyl-4-hydroxyphenyl)propane are not detailed in the available literature. The compound is described as a biologically active chemical, but specific in vitro activity data such as IC₅₀ values or assay results are not provided. Its primary use is in the synthesis of active compounds rather than as a pharmacologically active agent itself.
|
| ln Vivo |
Specific in vivo activity data for 2,2-Bis(3-phenyl-4-hydroxyphenyl)propane are not available in the consulted sources. The compound is used as a chemical intermediate for the synthesis of active compounds. No therapeutic or pharmacological in vivo studies have been reported.
|
| Enzyme Assay |
No specific protocols for enzyme/receptor binding assays are available for 2,2-Bis(3-phenyl-4-hydroxyphenyl)propane. As a chemical intermediate, it is not typically used in biological assays. For biological activity testing, standard assays could be employed, but none have been reported.
|
| Cell Assay |
No specific cell-based assay protocols are available for 2,2-Bis(3-phenyl-4-hydroxyphenyl)propane. The compound is used as a chemical intermediate rather than in cell-based assays. For potential biological activity, standard cell viability or cytotoxicity assays could be employed, but none have been reported.
|
| Animal Protocol |
No specific in vivo animal experiment protocols are available for 2,2-Bis(3-phenyl-4-hydroxyphenyl)propane. The compound is used as a chemical intermediate and is not intended for in vivo studies. No pharmacokinetic or efficacy studies in animal models have been reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2,2-Bis(3-phenyl-4-hydroxyphenyl)propane are not available. The compound is a chemical intermediate and is not intended for therapeutic use. No ADME studies have been reported. The compound's molecular weight is approximately 380.49 g/mol.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2,2-Bis(3-phenyl-4-hydroxyphenyl)propane are limited. As a bisphenol derivative, it may have potential endocrine-disrupting effects, similar to other bisphenols. However, comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
[1]. Chen D, et al. Bisphenol Analogues Other Than BPA: Environmental Occurrence, Human Exposure, and Toxicity-A Review. Environ Sci Technol. 2016 Jun 7;50(11):5438-53.
|
| Additional Infomation |
2,2-Bis(3-phenyl-4-hydroxyphenyl)propane (BisOPP-A) is a biologically active chemical used in the preparation and synthesis of active compounds. It is a bisphenol derivative with two phenyl and two hydroxyl groups. The compound is a research chemical used as a building block in organic synthesis and drug development. It is not approved for any clinical indication.
|
| Molecular Formula |
C27H24O2
|
|---|---|
| Molecular Weight |
380.49
|
| Exact Mass |
380.177
|
| CAS # |
24038-68-4
|
| PubChem CID |
13059052
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
567.4±50.0 °C at 760 mmHg
|
| Melting Point |
98-99ºC
|
| Flash Point |
252.8±24.7 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.629
|
| LogP |
6.35
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
459
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1C([H])=C([H])C(=C([H])C=1C1C([H])=C([H])C([H])=C([H])C=1[H])C(C([H])([H])[H])(C([H])([H])[H])C1C([H])=C([H])C(=C(C2C([H])=C([H])C([H])=C([H])C=2[H])C=1[H])O[H]
|
| InChi Key |
BKTRENAPTCBBFA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H24O2/c1-27(2,21-13-15-25(28)23(17-21)19-9-5-3-6-10-19)22-14-16-26(29)24(18-22)20-11-7-4-8-12-20/h3-18,28-29H,1-2H3
|
| Chemical Name |
4-[2-(4-hydroxy-3-phenylphenyl)propan-2-yl]-2-phenylphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6282 mL | 13.1409 mL | 26.2819 mL | |
| 5 mM | 0.5256 mL | 2.6282 mL | 5.2564 mL | |
| 10 mM | 0.2628 mL | 1.3141 mL | 2.6282 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
